Health care stocks were steady premarket Friday, with The Health Care Select Sector SPDR Fund (XLV) marginally higher and the iShares Biotechnology ETF (IBB) inactive.
BeiGene (BGNE) shares were up over 2% after the company said overnight it signed a global licensing deal with CSPC Zhongqi Pharmaceutical Technology for its experimental cancer therapy, SYH2039.
Geron (GERN) stock was over 1% higher after the company said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of Rytelo for the treatment of adult patients with transfusion-dependent anemia due to lower risk myelodysplastic syndromes.
Candel Therapeutics (CADL) shares were down past 33% after the company said overnight it priced an underwritten public offering of 10 million common shares at $6 apiece and pre-funded warrants to buy up to a total of 3.3 million shares of its common stock at $5.99 per warrant to raise about $80 million in gross proceeds.
Comments